ECOG: The Eastern Cooperative Oncology Group

ECOG Protocols Active as of 07/10/14

Click on the protocol number to view the NCI's PDQ description of the protocol.


E1A10 A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients with Relapsed Waldenstrom's Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom's Macroglobulinemia (PhaseII)
Activation Date: 20-jul-2011
ECOG Participants(requires Adobe Acrobat)
E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Activation Date: 13-nov-2013
E3A05 Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders
Activation Date: 30-aug-2006
ECOG Participants(requires Adobe Acrobat)
E3A06 Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Activation Date: 05-oct-2010
S1211 A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Activation Date: 01-oct-2013
S1304 A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory
Activation Date: 18-oct-2013

ECOG Home Page

How to contact ECOG

All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 07/10/14